New research from the University of Michigan Life Sciences Institute is building a bridge from nature's chemistry to greener, more efficient synthetic chemistry.
Researchers from RUDN University and Institute of Biomedical Chemistry of the Russian Academy of Sciences have identified an alternative mechanism for the effective antitumor drug -- an enzyme called L-asparaginase. Some isoenzymes of L-asparaginase block the growth of telomeres (region of repetitive nucleotide sequences at each end of a chromosome) on DNA molecules, and this limits the number of divisions of a cancer cell. This effect is reported in the Biochemical and Biophysical Research Communications.
Celgene Corporation recently announced results from two phase 3 trials evaluating the efficacy and safety of the drug ozanimod. Ozanimod was invented by scientists at The Scripps Research Institute (TSRI).
Researchers from RUDN University conducted an effective three-component reaction, obtaining unusual organic compounds. The latter are structurally similar to a number of biologically active compounds -- which makes it possible to use them in pharmaceutics (for example, as anti-tumor drugs and agents for Alzheimer's disease). The results of the work are presented in the journal Mendeleev Communications.
Employees of RUDN University are actively involved in the development of chemical compounds isoxazoles, capable of suppressing the growth of malignant tumors. The results of the study were published in Tetrahedron.
A revolutionary new technique to create radioactive molecules, pioneered in the lab of Princeton University chemistry professor David MacMillan, has the potential to bring new medicines to patients much faster than before -- using light. While the previous approach took months, MacMillan's photocatalytic process replaces hydrogen with tritium in just hours.
A new SLAS Technology review article by researchers at the University of Southern California and the University of California, Los Angeles, sheds light on the growing number and more sophisticated designs of theranostic nanoparticles.
German scientists have developed a novel nuclear medicine test that can determine whether a kidney transplant patient has developed infection in the transplanted tissue. The study, which utilizes positron emission tomography/magnetic resonance imaging (PET/MRI), is presented in the November issue of The Journal of Nuclear Medicine.
Scientists from RUDN University took an active part in the development of a chemical compound that would help to stop convulsions during epileptic seizures. The results of the study were published in Chirality.
Connecting cancer immunotherapy drugs such as anti-CTLA4 and anti-PD-L1 to peptides that bind to tissues in and around tumors enhanced their effects while limiting adverse events.